298 related articles for article (PubMed ID: 23214190)
1. Cardiotoxicity of oncological treatment in children.
Kucharska W; Negrusz-Kawecka M; Gromkowska M
Adv Clin Exp Med; 2012; 21(3):281-8. PubMed ID: 23214190
[TBL] [Abstract][Full Text] [Related]
2. High risk of symptomatic cardiac events in childhood cancer survivors.
van der Pal HJ; van Dalen EC; van Delden E; van Dijk IW; Kok WE; Geskus RB; Sieswerda E; Oldenburger F; Koning CC; van Leeuwen FE; Caron HN; Kremer LC
J Clin Oncol; 2012 May; 30(13):1429-37. PubMed ID: 22473161
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
4. Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.
Sieswerda E; Kremer LC; Vidmar S; De Bruin ML; Smibert E; Sjöberg G; Cheung MM; Weintraub RG
Pediatr Blood Cancer; 2010 Apr; 54(4):579-84. PubMed ID: 20014238
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of cardiotoxicity induced by anthracyclines.
Elliott P
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
[TBL] [Abstract][Full Text] [Related]
6. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
7. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group.
Shankar SM; Marina N; Hudson MM; Hodgson DC; Adams MJ; Landier W; Bhatia S; Meeske K; Chen MH; Kinahan KE; Steinberger J; Rosenthal D;
Pediatrics; 2008 Feb; 121(2):e387-96. PubMed ID: 18187811
[TBL] [Abstract][Full Text] [Related]
8. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
Bustová I
Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
[TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].
Nelson-Veniard M; Thambo JB
Bull Cancer; 2015; 102(7-8):622-6. PubMed ID: 25935231
[TBL] [Abstract][Full Text] [Related]
10. [High-resolution electrocardiography in monitoring myocardial damage after therapy with anthracyclines in children].
Mladosievicová B; Foltinová A; Bernadic M; Petrásová H; Hulín I
Bratisl Lek Listy; 1996 May; 97(5):289-97. PubMed ID: 8705327
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
Pai VB; Nahata MC
Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
[TBL] [Abstract][Full Text] [Related]
12. Present risk of anthracycline or radiation-induced cardiac sequelae following therapy of malignancies in children and adolescents.
Chen C; Heusch A; Donner B; Janssen G; Göbel U; Schmidt KG
Klin Padiatr; 2009; 221(3):162-6. PubMed ID: 19437364
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic possibilities of late cardiotoxic sequelae of chemotherapy with anthracyclines].
Elbl L; Hrstková H; Chaloupka V; Novotný J
Vnitr Lek; 2002 Oct; 48(10):981-8. PubMed ID: 16737150
[TBL] [Abstract][Full Text] [Related]
14. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
[TBL] [Abstract][Full Text] [Related]
15. [Treatment-related cardiotoxicity in childhood cancer survivors: Risk factors and follow-up].
Fresneau B; Fayech C; Butel T; Haddy N; Valteau-Couanet D; Ou P
Rev Med Interne; 2017 Feb; 38(2):125-132. PubMed ID: 27639916
[TBL] [Abstract][Full Text] [Related]
16. Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography.
Galderisi M; Marra F; Esposito R; Lomoriello VS; Pardo M; de Divitiis O
Cardiovasc Ultrasound; 2007 Jan; 5():4. PubMed ID: 17254324
[TBL] [Abstract][Full Text] [Related]
17. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
18. Anticancer agents and cardiotoxicity.
Ng R; Better N; Green MD
Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
[TBL] [Abstract][Full Text] [Related]
19. [Cardiotoxicity of antracycline treatment in the light of new biochemical diagnostic options].
Urbanová D; Mladosievicová B
Vnitr Lek; 2007 Jun; 53(6):669-77. PubMed ID: 17702127
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of anthracycline-induced cardiotoxicity.
Jannazzo A; Hoffman J; Lutz M
Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
